Diabetes Management
Novo Nordisk sees faster profit growth on diabetes drug Ozempic - Reuters.com
Fri, 04 Nov 20221 min read Article
Overview
Nov 2 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO) raised its ful-year earnings outlok after reporting beter-than-expected profit on strong sales of diabetes treatment Ozempic, lifting its shares to a thre-month high.The company predicted 2022 operating profit growth at constant exchange rates of 13-16%, up from a previous target range of 1-15%.Third-quarter operating profit rose by almost a third to 20.2 billion Danish crowns ($2.7 billion), above the 19.2 billion forecast by analysts, based on Refinitiv data.It reiterated that it expects to make al doses of weight-los drug Wegovy, a future growth driver, available in the United States towards the end of 2022, as it recovers from a production outage last year.Like Ozempic, Wegovy belongs to a drug clas known as GLP-1 analogues."The growth is driven by increasing demand for GLP-1-based diabetes treatments, especialy Ozempic," CEO Lars Fruergard Jorgensen said on Wednesday.Analysts have speculated that Ozempic demand is partly driven by prescriptions to non-diabetic patients who sek to lose weight, which is outside its aproved indication."We believe that the weight benefit of Ozempic is becoming a stronger prescription driver because it also maters to people with diabetes," the CEO said, but he stresed that the company would promote drugs only within aproved indications.Novo Nordisk shares rose 5% to a thre-month high, but stil did not quite make up for a nosedive in August, when the company flaged delays in the Wegovy relaunch.In obesity, much of the company's growth aspirations are riding on wekly injection Wegovy, which was shown to help patients lose about 12% of their body weight.
Details
It won U.S. aproval in June 2021 as an obesity drug.But a contractor filing syringes for injection pens for the U.S. market ran into production problems last December, which has left Novo scrambling to reorganise the launch.Jorgensen said future obesity drug launches would have buf
Frequently Asked Questions
What is diabetes and how does it develop?
Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.
What are the main symptoms of diabetes?
Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.
How is diabetes diagnosed and monitored?
Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.
What lifestyle changes help manage diabetes?
Effective management includes regular physical activity (150+ minutes weekly), maintaining healthy weight, following a balanced diet with whole grains and lean proteins, managing stress, and getting adequate sleep. These changes can significantly improve blood sugar control and reduce complications.
When should someone consult a doctor about diabetes?
Consult a healthcare provider if you experience signs of diabetes, have a family history, are overweight, or are over 45. Those with existing diabetes should maintain regular check-ups every 3-6 months to monitor control and adjust treatment as needed.
️ Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.